ASTRAZEN

AstraZeneca Pharma India share price & financials

Price
₹8,023.5
Market cap
₹16.9k Cr
Sector
Healthcare
Calls analysed
5
Latest concall · Q1 FY26 · call held 14 Aug 2025

Astrazeneca Phar Q1 FY26

Revenue ₹1,716 cr +32%EPS ₹46.3 −27%

Revenue ₹1,716 cr (+32% YoY); EPS ₹46.3 (−27% YoY). Revenue from operations for FY24-25 reached ₹1,716 crore, representing a 32% YoY growth.

Read the full call →

What AstraZeneca Pharma India Limited does

AstraZeneca Pharma India Limited is the Indian listed subsidiary of the UK-headquartered AstraZeneca group, engaged in the marketing and commercialisation of specialist prescription medicines developed by the global parent rather than in-house drug discovery. It earns by selling branded oncology, cardiovascular/renal/metabolic, respiratory/immunology and rare-disease therapies through hospitals, oncologists, cardiologists and other specialist physicians across India. The company closed its domestic manufacturing plant during FY24-25 as part of a strategic shift toward a specialist, launch-led, import/marketing-driven model rather than local production. It also runs patient-access, early-diagnosis and disease-awareness partnerships (with hospitals, government health departments and diagnostic labs) to support uptake of its therapies.

Segments

  • Oncology
  • Biopharmaceuticals
  • Rare Disease
Indian Pharmaceutical Market (IPM) rank
#40 among IPM companies
Oncology brand market position
No.1 lung cancer brand (Tagrisso) and No.1 ovarian cancer brand in India
New medicine and indication approvals since 2023
14
Domestic manufacturing footprint
No domestic manufacturing plant (closed in FY24-25); operates an import/marketing-led commercial model
Precision Clinics network for severe-asthma diagnosis
200+ clinics established
Centres of Excellence (COEs) developed
10
Company website

Guidance record · Q1 FY26

what the last two calls moved 8 tracked 2 delivered 3 missed 3 open
  • Dividend Payout Ratio delivered said Q4 FY22 Promised: Increase towards 50% Q1 FY26: Company declared a dividend of ₹32 per share on an EPS of ₹46.3, resulting in a payout ratio of 69.1%, significantly exceeding the 50% mark.
  • Long-term Revenue went quiet said Q4 FY21 Promised: $1 billion by FY30 Q1 FY26: An analyst references the past 'billion dollar' vision, but management does not confirm, update, or recommit to this specific target.
  • Asset Sale at risk said Q1 FY25 Promised: Completion of sale in next 12 to 15 months Q1 FY26: Twelve months after the promise, management discusses costs related to the plant closure but does not confirm the completion of the sale or the realization value. The deadline is at risk.

All 8 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 29.8%, net profit down 32.1% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue408 440 480 526 559 +37%612 +39%579 +21%683 +30%
EBITDA53 77 86 81 75 +42%45 −42%61 −29%49 −40%
Net profit38 31 58 56 54 +42%33 +6%45 −22%38 −32%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −24.8% 1Y

₹7k₹8k₹9k₹10kSept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹8,996 on 10 Sept 2025 → ₹6,764.5. High ₹9,827.5 (3 Nov 2025), low ₹6,764.5 (11 Sept 2026).

Financials, as filed

Revenue grew 31.4% a year over 3 years, FY23 to FY26. Operating margin narrowed to 11.5%.

Year endingFY23FY24FY25FY26
Revenue₹1.0k Cr₹1.3k Cr₹1.7k Cr₹2.3k Cr
Operating profit₹166 Cr₹184 Cr₹254 Cr₹262 Cr
Operating margin16.6%14.2%14.8%11.5%
Interest₹0 Cr₹1 Cr₹1 Cr₹5 Cr
Depreciation₹16 Cr₹16 Cr₹40 Cr₹30 Cr
Net profit₹99 Cr₹161 Cr₹115 Cr₹188 Cr
Net margin9.9%12.4%6.7%8.3%
Cash from operations₹58 Cr₹28 Cr₹65 Cr₹-15 Cr
Free cash flow₹53 Cr₹18 Cr₹64 Cr₹-18 Cr
ROCE31.0%31.0%33.0%29.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹5 Cr₹5 Cr₹5 Cr₹5 Cr₹5 Cr₹5 Cr
Reserves₹451 Cr₹506 Cr₹584 Cr₹707 Cr₹794 Cr₹868 Cr
Borrowings₹12 Cr₹9 Cr₹7 Cr₹5 Cr₹35 Cr₹111 Cr
Other liabilities₹306 Cr₹337 Cr₹389 Cr₹362 Cr₹781 Cr₹1.0k Cr
Total liabilities₹775 Cr₹857 Cr₹985 Cr₹1.1k Cr₹1.6k Cr₹2.0k Cr
Fixed assets₹81 Cr₹74 Cr₹69 Cr₹67 Cr₹40 Cr₹117 Cr
Capital work in progress₹4 Cr₹2 Cr₹1 Cr₹0 Cr₹0 Cr₹0 Cr
Investments₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Other assets₹690 Cr₹780 Cr₹915 Cr₹1.0k Cr₹1.6k Cr₹1.9k Cr
Total assets₹775 Cr₹857 Cr₹985 Cr₹1.1k Cr₹1.6k Cr₹2.0k Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, DIIs added +1.53 pp while the public trimmed −1.17 pp. The shareholder count shrank 15% to 29,338.

Promoters
75.0%
FIIs
2.7%
DIIs
6.1%
Public
16.2%

Since Jun 2025

  • DIIs +1.53 pp
  • Public −1.17 pp
  • FIIs −0.35 pp

How it drifted, 12 quarters

Over this window DIIs went from 2.4% to 6.1% — +3.7 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 75.0%, FIIs 2.7%, DIIs 2.4%, Public 19.9%.Dec '23: Promoters 75.0%, FIIs 2.7%, DIIs 2.8%, Public 19.6%.Mar '24: Promoters 75.0%, FIIs 2.7%, DIIs 3.8%, Public 18.5%.Jun '24: Promoters 75.0%, FIIs 2.8%, DIIs 5.0%, Public 17.2%.Sep '24: Promoters 75.0%, FIIs 2.9%, DIIs 5.1%, Public 17.0%.Dec '24: Promoters 75.0%, FIIs 2.9%, DIIs 5.2%, Public 16.9%.Mar '25: Promoters 75.0%, FIIs 2.9%, DIIs 4.7%, Public 17.4%.Jun '25: Promoters 75.0%, FIIs 3.0%, DIIs 4.5%, Public 17.4%.Sep '25: Promoters 75.0%, FIIs 2.7%, DIIs 5.3%, Public 17.0%.Dec '25: Promoters 75.0%, FIIs 2.7%, DIIs 5.5%, Public 16.7%.Mar '26: Promoters 75.0%, FIIs 2.8%, DIIs 5.8%, Public 16.4%.Jun '26: Promoters 75.0%, FIIs 2.7%, DIIs 6.1%, Public 16.2%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 1 holder trimming and 0 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of AstraZeneca Pharma India Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
AstraZeneca Pharmaceuticals AB 75.00%unchanged
Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund(Various Schemes) Mutual fund2.89%unchanged
Tejas Bhalchandra Trivedi 2.68%unchanged
Shivani Tejas Trivedi 2.33%−0.07 pp
ICICI PRUDENTIAL - Various Schemes Mutual fund1.39%+0.27 pp
Bandhan - Various Schemes Mutual fund1.28%+0.15 pp
Prashant Jain 1.10%unchanged
AstraZeneca AB 0.00%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Mutual funds in ASTRAZEN

Filings to Aug 2026

0 new, 0 added, 0 trimmed, 0 sold out — net +0.00 L shares (+0.0%).

Held by funds
₹504 Cr
2 schemes
Biggest holder
Nippon India Small Cap Fund
₹460 Cr · 0.6% of that fund
SchemeHoldingLast month
Nippon India Small Cap Fund Nippon India Mutual Fund₹460 Crheld
Nippon India Pharma Fund Nippon India Mutual Fund₹43 Crheld

HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.

Mutual funds Aug 2026

0 added, 0 trimmed — net 0 shares (+0.0%)

Funds are sitting on
+131%
vs est. average cost
Held by funds
₹504 Cr
2 schemes · ≈ 3.4% of the company
Biggest holder
Nippon India Small Cap Fund
₹460 Cr · 0.6% of that fund

Shares held by these funds +23%

Aug '23 7.24 L shares Jul '26

What the price assumes

Growth trap

To justify its price of ₹6764, this stock must grow earnings at 46% every year for 7 years. Our analysis caps realistic growth at ~24%. At that growth it is worth ₹2323 — downside of 66%.

Growth the price implies
46.0% a year
for 7 years, fading to 4%
It has actually compounded at
23.8% a year
net profit, FY23–FY26 · EPS 23.6%
The gap
0.2 pp
-66% downside if it only repeats history
Price today ₹6,764.5 Value at the reference growth ₹2,323.22

Change the assumptions yourself →

All earnings calls (5)

Read the Q1 FY26 call →

Learn to analyse AstraZeneca Pharma India Limited

Guides on how to read this kind of business and the numbers that matter.